News Center

EASL 2026 | Doer Biologics Presents Results from a Phase 2 Study of DR10624 in Severe Hypertriglyceridemia on Liver Fat and Improvement of Hepatic Metabolic Markers

2026/05/28

Read more

AHA-BCVS 2026 | Doer Biologics Presents Preclinical Research Results of Innovative Triple Agonist DR10624 in Anti-Atherosclerosis

2026/05/27

Read more

AACR 2026|Doer Bio Presents DR319-DP, a Bispecific Bipayload ADC, Demonstrating Breakthrough Potential in Overcoming Efficacy and Resistance Challenges in Solid Tumors

2026/05/25

Read more

Doer Biologics Honored as Hangzhou Quasi-Unicorn for Sixth Consecutive Year

2026/04/24

Read more

AACR 2026 | Doer Biologics Presents Preclinical Data on Bispecific Dual-Payload ADC

2026/04/16

Read more

Doer Biologics to Present Preclinical Results of DR319 Project at AACR 2026

2026/03/24

Read more

Approval of IND Application in China for Doer's DR30206 Injection Combined with Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

2026/03/03

Read more

Dr. Yongliang Fang on Endpoints News:Chinese biotech unveils first-in-class tri-agonist for high lipids

2025/12/31

Read more

Doer Biologics Announces First Patient Dosed in Phase Ib Clinical Trial of DR30206 for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2025/11/21

Read more

Doer Biologics' Globally First-in-Class Drug DR10624 Phase II Clinical Data Presented in Opening Session at AHA 2025

2025/11/11

Read more